Carregant...
First‐in‐man–proof of concept study with molidustat: a novel selective oral HIF‐prolyl hydroxylase inhibitor for the treatment of renal anaemia
AIMS: Insufficient erythropoietin (EPO) synthesis is a relevant cause of renal anaemia in patients with chronic kidney disease. Molidustat, a selective hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitor, increases endogenous EPO levels dose dependently in preclinical models. We examined...
Guardat en:
| Publicat a: | Br J Clin Pharmacol |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6005617/ https://ncbi.nlm.nih.gov/pubmed/29575006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13584 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|